solid first-quart phase studi cf tripl combo
initi acceler timelin
key progress develop front initi phase studi
two tripl combo would address cf popul success
design studi clear-cut acceler timelin compar
previou pivot studi kalydeco orkambi result move
estim launch date vertex tripl combo enter market fourth
thursday april market close vertex report first quarter
financi result beat expect top bottom line cystic
fibrosi cf franchis sale came estim orkambi sale approxim
million estim million beat consensu
million kalydeco sale came approxim million higher estim
million consensu million bottom line non-gaap net incom
quarter million per share beat estim million
per share consensu estim million per share exhibit
compani end quarter approxim billion cash cash equival
quarter second quarter composit two tripl combo
symdeko tezacaftor ivacaftor symdeko tripl combo
studi het/min mutat one allel minim function
mutat popul homozyg popul studi
design support ex-u registr compani strategi test
two differ next-gen corrector-bas combin parallel intend help identifi
benefici regimen patient maxim speed market notabl
het/min studi primari efficaci assess week safeti assess
week much acceler develop timelin compar kalydeco
orkambi whose durat pivot studi month efficaci one year
safeti follow-up
return equiti ttm
biopharmaceut compani focus develop commerci therapi
cystic fibrosi compani lead asset kalydeco kalydeco lumacaftor combo registr next-
gener combin clinic develop
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
maintain market perform rate increas fair valu estim vertex share
exhibit base move vertex launch tripl combo earlier mention decreas market
share potenti competit cf market model acknowledg vertex lead posit field npv
model valu compani cf franchis per share togeth net cash per share end
deriv fair valu vertex share note model includ valu program cf gene
therapi program outsid cf excit scientif medic breakthrough led vertex pois
solv cf problem market perform thesi vertex share sole base view competit
market dynam vertex embark execut phase studi tripl combo proof-of-concept data
galapago glpg outperform well proteostasi pti tripl combo also
read throughout earli competitor data par vertex tripl combo vertex share might
neg affect data match vertex triple-combo profil expect vertex share
final phase studi design shorten trial durat expedit timelin approv exhibit estim
top-lin data het/min patient studi avail earli two set phase studi
ident design target enrol patient het/min trial patient
homozyg trial patient studi random receiv symdeko placebo
symdeko het/min studi primari efficaci endpoint mean absolut chang lung function baselin
week compar placebo safeti evalu week follow long-term open-label extens
homozyg studi patient begin four-week run-in symdeko follow anoth four week
ad next-gener corrector placebo roll long-term tripl combo extens primari efficaci
endpoint studi mean absolut chang lung function end run-in period end four-
week experiment period tripl combo patient versu placebo symdeko patient regulatori submiss
homozyg patient safeti evalu throughout cours studi supplement
safeti data regimen correspond trial het/min patient note prior pivot studi orkambi
symdeko efficaci safeti endpoint contrast current phase tripl combin studi
het/min patient cut half greatli acceler timelin approv high unmet need popul
abil supplement homozyg safeti data long-term result larger set het/min patient help
creat stronger data packag patient also shorten time regulatori submiss second
phase ii data qd support potenti replac bid kalydeco novel tripl combin therapi
expect gain clariti incorpor phase studi follow compani
discuss fda later year deuter version kalydeco licens
allow once-daili dose posit becom new potenti backbon tripl combo
regimen note kalydeco compon tripl combo dose twice daili top-lin result
phase ii studi evalu part tripl combin regimen het/min patient show mean absolut
improv lung function combin tezacaftor tezacaftor
respect result similar efficaci safeti compar prior phase ii studi compani tripl
combin includ kalydeco support advanc phase test compani origin
intend start around howev fda view new chemic entiti agenc request
addit dose rang data includ potenti evalu monotherapi compani pursu
phase develop manag continu discuss path forward agenc await updat
determin advanc clinic
maintain market perform rate increas fair valu estim vertex share
exhibit base follow rational model chang npv model valu compani cf franchis
per share togeth net cash per share end deriv fair valu vertex share
note model includ valu program cf gene therapi program outsid cf
program remain upsid valuat
modifi cf market model give vertex peak market share year-end previous
push back estim competitor entri year-end earli cf popul larg
alreadi identifi estim rel rapid uptak tripl combin evidenc kalydeco reach close
penetr unit state three quarter launch estim global market cf modul
peak billion declin billion ad competit drive net price continu
estim probabl vertex success launch tripl combin push estim launch first
quarter second quarter billion peak global sale previou estim
million declin thereaft billion global sale last year model franchis valid patent
term bell-shap cash flow curv constitut basi valuat market perform rate
competit pursuit galapago partner recent push first fulli proprietari tripl
combin clinic test initi data expect third quarter although continu believ
vertex highest chanc success get first tripl combo market also note competit far
behind particular note galapago partner recent began enrol phase ii falcon studi
exhibit compani first trial set evalu proprietari tripl combin falcon two-part trial evalu
potenti corrector corrector part one studi enrol eight homozyg
patient receiv two week add anoth two week part two enrol anoth cohort
patient second cohort het/min patient subject receiv two
week follow addit anoth two week although dose detail disclos manag
note least one compon combin increas part one part two data part one
studi anticip third quarter
proprietari tripl enter clinic previous guid compani plan begin test
second tripl regimen clinic compris second-gener potenti combin
note pk profil suitabl once-daili dose compar
metabolit long half-lif one month may may optim combin other
once-daili regimen third tripl combin regimen second-gener corrector
expect potent like enter clinic second half although note compani
still process character phase studi tripl combo demonstr adequ
competit efficaci safeti profil could initi phase studi toward late best-cas scenario
estim estim program month behind vertex believ galapago
plan path tripl combo face much higher hurdl compar vertex tripl combo strategi
trivial put three compound limit human experi togeth success first tri note
three tripl combo design once-daili dose
upcom catalyst includ initi data part one phase studi symdeko third quarter
updat path forward top-lin data phase studi symdeko
earli nda submiss approv tripl combin second half initi proof-of-concept data
vertex program outsid cystic fibrosi next one two year
risk market perform rate vertex includ stronger competit data cf inabl develop
tripl combo therapi setback relat clinic preclin busi develop activ
incom world-wide combo worldiwid sale incl orkambi cf tripl combo world-wide sales- hcv net royalti collabor total restructur expens total oper interest exchang convert notes- incom pre-tax incom net incom loss attribut non-controlling net incom loss atribut vertex non- incom compens compens transaction/hcv-rel septemb transactions- intang asset impair charg net tax- collabor crispr- restructur one-tim total non- weight averag share outstand averag share outstand compani report william blair compani incorporatedincom statement dollar thousand william blair
compani reportsexhibit incorporateddesign phase tripl combo studi het/min patientsweek efficaci endpointweek durat analysi het/min approvalweek durat analysisto support tez/iva compani reportsexhibit incorporateddesign phase tripl combo studi patientsweek efficaci tez/iva william blair
dollar thousand drugpeak salesstag ofdevelopmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuekalydeco cystic fibrosi gate marketedfebruari combo cystic homozyg market orkambi pre-registr kalydeco/tezacaftor juli combofor cystic phase year-end present valu addit gain loss fair includ cost directli relat program abovesourc compani report william blair compani estimatesexhibit incorporatedsum-of-part fair weekssourc galapago nv exhibit incorporateddesign galapago phase ii falcon trial import disclosur
